• You are here
  • Rauh Lab

Bringing Chemistry to Life

Rauh Lab

The Rauh group focuses on chemical biology, protein X-ray crystallography and medicinal chemistry research. We employ organic synthesis, structural biology, structure-based ligand design, biochemical and cellular compound screening, as well as target identification for the development of inhibitors and functional probes to target proteins with relevance to cancer.

Over the last decade, the Rauh group has collaborated very successfully with oncologists from university hospitals throughout NRW on translational aspects of acquired drug resistance in lung cancer and pioneered the field of chemical oncology.

We developed the widely applicable FLiK technologies (Fluorescent Labels in Kinases), which allow for the identification and characterization of allosteric kinase modulators from compound libraries in high-throughput. The Rauh Lab has established a Robotics Assisted Screening Platform for Efficient Ligand Discovery (RASPELD) that can be utilized for a variety of screening campaigns.

Prof. Daniel Rauh is co-founder of the Zentrum für integrierte Wirkstoffforschung (ZIW) and coordinates the “Drug Discovery Hub Dortmund” (DDHD) at TU Dortmund University, which translates basic academic research into pharmaceutical application.

 

e:Medium Article on Borussertib

Lecture Series: Modern Drug Discovery - WS 2019/2020

UA Ruhr-Forscher entwickeln gemeinsam Grundlagen für gezielte Krebstherapie

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer